Diazoxide-unresponsive congenital hyperinsulinism associated with ABCC8 nonsense mutation

نویسندگان

  • Suhaimi Hussain
  • Sian Ellard
  • Sarah Flanagan
چکیده

Case presentation A baby boy with birth weight of 2.4kg at 35 weeks was born via Caesarian section. The boy was allowed feeding on demands, however he had the first onset of hypoglycemia at 2 hours of life. His blood sugar ranged from low reading to 2.5 mmol/L. The patient was treated with boluses of intravenous dextrose D10% followed by maintenance dextrose with its increasing strength in order to treat the refractory hypoglycemia. In addition to that intravenous hydrocortisone and glucagon infusion were started. The patient’s blood sugar could only be maintained > 3.0mmol/L after a glucose load of 30mg/kg/min and a glucagon infusion of 50mcg/kg/hour. During hypoglycemia, the insulin level was 19.6 pmol/L (17.8-173.0) and blood ketone was negative. Oral diazoxide was started at 5.0mg/kg/day in divided doses combined with chlorothiazide 7.0 mg/kg/day. Diazoxide was titrated up to 20.0mg/kg/day as he had a poor response even after 1 week of the treatment. Apart from that oral nifidipine 2.5 mg/kg/day in divided doses was also started after a few days with the combination therapy. Only after starting octreotide infusion a good rise of blood sugar was seen within 1 hour and the glucose load could be brought down and the other drugs were off. The boy was discharged with subcutaneous octreotide infusion at 2mcg/ hour via portable insulin pump. Results The boy is heterozygous for an ABCC8 nonsense mutation, p.R934*. A second ABCC8 mutation has not been found and sequencing of the KCNJ11 gene failed to detect a change from the normal sequence. He has inherited the mutation from his father; a focal lesion is therefore possible. 18F-DOPA PET-CT scanning is recommended and if a focal lesion is identified and surgically resected, microsatellite analysis of the DNA can be undertaken to confirm loss of heterozygosity.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Nifedipine in Congenital Hyperinsulinism- A Case Report

Congenital hyperinsulinism (CHI) is the commonest cause of persistent hypoglycemia in neonates. Diazoxide is the first-line drug in its treatment, but the more severe cases are usually diazoxide-resistant. Recessive ABCC8 and KCNJ11 mutations are responsible for most (82%) of the severe diazoxide-unresponsive CHI. Oral nifedipine has been effective in isolated cases of CHI. Successful treatment...

متن کامل

A novel mutation of ABCC8 gene in a patient with diazoxide-unresponsive congenital hyperinsulinism

Congenital hyperinsulinism (CHI) is a rare condition that can cause irreversible brain damage during the neonatal period owing to the associated hypoglycemia. Hypoglycemia in CHI occurs secondary to the dysregulation of insulin secretion. CHI has been established as a genetic disorder of islet-cell hyperplasia, associated with a mutation of the ABCC8 or KCNJ11 genes, which encode the sulfonylur...

متن کامل

A novel case of compound heterozygous congenital hyperinsulinism without high insulin levels

BACKGROUND Congenital hyperinsulinism leads to unregulated insulin secretion and hypoglycemia. Diagnosis can be difficult and genetic testing may be warranted. CASE This patient initially presented at 11 months with seizure activity secondary to severe hypoglycemia. Her diagnostic evaluation included genetic studies, which confirmed congenital hyperinsulinism. A novel combination of mutations...

متن کامل

Diazoxide-Unresponsive Congenital Hyperinsulinism in Children With Dominant Mutations of the β-Cell Sulfonylurea Receptor SUR1

OBJECTIVE Congenital hyperinsulinemic hypoglycemia is a group of genetic disorders of insulin secretion most commonly associated with inactivating mutations of the β-cell ATP-sensitive K(+) channel (K(ATP) channel) genes ABCC8 (SUR1) and KCNJ11 (Kir6.2). Recessive mutations of these genes cause hyperinsulinism that is unresponsive to treatment with diazoxide, a channel agonist. Dominant K(ATP) ...

متن کامل

Congenital hyperinsulinism: clinical and molecular characterisation of compound heterozygous ABCC8 mutation responsive to Diazoxide therapy

BACKGROUND Mutations in ABCC8 and KCNJ11 are the most common cause of congenital hyperinsulinism (CHI). Recessive as well as dominant acting ABCC8/KCNJ11 mutations have been described. Diazoxide, which is the first line medication for CHI, is usually ineffective in recessive ABCC8 mutations. We describe the clinical and molecular characterisation of a recessive ABCC8 mutation in a CHI patient t...

متن کامل

Clinical and molecular characterisation of 300 patients with congenital hyperinsulinism

BACKGROUND Congenital hyperinsulinism (CHI) is a clinically heterogeneous condition. Mutations in eight genes (ABCC8, KCNJ11, GLUD1, GCK, HADH, SLC16A1, HNF4A and HNF1A) are known to cause CHI. AIM To characterise the clinical and molecular aspects of a large cohort of patients with CHI. METHODOLOGY Three hundred patients were recruited and clinical information was collected before genotypi...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:

دوره 2015  شماره 

صفحات  -

تاریخ انتشار 2015